MedTrace Logo

STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)

NCT07743138 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-08-03

No results posted yet for this study

Summary

To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ACC or PPGL.

Conditions

  • Phase II
  • Ivonescimab
  • Evaluate
  • Unresectable/Metastatic Adrenocortical Carcinoma
  • ACC
  • Unresectable Pheochromocytoma
  • PPGL

Interventions

DRUG

Ivonescimab

Given by IV

Sponsors & Collaborators

  • Summit Therapeutics

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Matthew Campbell, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-02-07
Primary Completion
2028-05-01
Completion
2030-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07743138 on ClinicalTrials.gov